22 May 2013
Keywords: map, tempo, migraine, drug, sees, strong, ph
Article | 12 March 2007
The USA's MAP Pharmaceuticals says that its candidate migraine treatment met its primary endpoints in a Phase II clinical program ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 April 2007
13 August 2007
21 May 2013
© 2013 thepharmaletter.com